EUVIMEDEUVIMED entdecken
Crossref

ROS-Activated Peptide-Based Prodrug for Chemoselective Covalent Targeting in Cancer Cells

Shijin Zhang iD, Qinchuan Wei, Jiarong Lv, Xuewen Gong, Bingrui Wang, Zhiruo Ren, Cailing Wei, Zhihao Guo, Ji-Liang Li iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Shijin Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center of Ophthalmology and Optometry, School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenz…. Hauptthemen laut MEDLINE: Prodrugs, Reactive Oxygen Species, Antineoplastic Agents, Peptides. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Eye Hospital Wenzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of covalent drugs has renewed interest in strategies that achieve high selectivity while minimizing off-target reactivity. Herein, we report IRS1, a peptide-based prodrug comprising an integrin-targeting RGD motif, an ROS-responsive thiomorpholine unit, and a chlorambucil-derived covalent warhead for efficient cancer inhibition. Under physiological conditions, IRS1 self-assembles into nanoparticles and preferentially accumulates in uveal melanoma (UM) cells via integrin-mediated targeting. Within the tumor microenvironment, ROS-triggered oxidation of thiomorpholine induces a hydrophobic-to-hydrophilic transition, driving the nanoparticle-to-nanofibril transformation and exposing the chlorambucil moiety. This enables covalent conjugation with the thiol groups of DR4/DR5 on the cell membrane. IRS1 effectively disrupts membrane integrity, activates extrinsic apoptosis, and induces cancer cell death in vitro. In UM xenograft models, IRS1 shows potent antitumor efficacy with reduced systemic toxicity, highlighting a peptide-reconfiguration strategy for tumor-selective covalent therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsReactive Oxygen SpeciesAntineoplastic AgentsPeptidesHumansAnimalsCell Line, TumorApoptosisMiceXenograft Model Antitumor AssaysMice, NudeChlorambucil

Substanzen

ProdrugsReactive Oxygen SpeciesAntineoplastic AgentsPeptidesChlorambucil

Autor:innen und Institutionen

  • National Engineering Research Center of Ophthalmology and Optometry, School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
  • University of Chinese Academy of Sciences Wenzhou Institute, Wenzhou 325001, China.

ORCID-Profile: Shijin Zhang, Ji-Liang Li

Förderung

  • Eye Hospital Wenzhou Medical University

Zitieren

APA

Zhang, S., Wei, Q., Lv, J., Gong, X., Wang, B., Ren, Z., Wei, C., Guo, Z., & Li, J. L. (2026). ROS-Activated Peptide-Based Prodrug for Chemoselective Covalent Targeting in Cancer Cells. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02472

Vancouver

Zhang S, Wei Q, Lv J, Gong X, Wang B, Ren Z, et al. ROS-Activated Peptide-Based Prodrug for Chemoselective Covalent Targeting in Cancer Cells. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02472

BibTeX
@article{Zhang2026,
  author = {Zhang, Shijin and Wei, Qinchuan and Lv, Jiarong and Gong, Xuewen and Wang, Bingrui and Ren, Zhiruo and Wei, Cailing and Guo, Zhihao and Li, Ji-Liang},
  title = {ROS-Activated Peptide-Based Prodrug for Chemoselective Covalent Targeting in Cancer Cells},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02472}
}
Kostenlos starten →